[A23-83] Durvalumab (malignant biliary tract cancer [BTC]) – Addendum to Commission A23-26
Last updated 05.10.2023
Project no.:
A23-83
Commission:
Commission awarded on 08.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
First-line treatment of adults with unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin
Unchanged after addendum: indication of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-26 | Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision